Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levetiracetam for Seizure Prophylaxis in Aneurysmal Subarachnoid Hemorrhage
NCT01935908Phase 4Withdrawn
- Sponsor
- Vanderbilt University Medical Center
- Start
- May 2013
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of levetiracetam in epilepsy (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Randomization Yield at 6 months. Planned start May 2013; status: withdrawn.
02
Drugs
levetiracetam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT01935908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01935908.